Mankind Pharma Ltd is acquiring Bharat Serum and Vaccines Ltd (BSV) from Advent International for an enterprise value of ₹13,630 crore.

BSV is a branded specialty pharma platform in women’s health and critical care.

It is present in branded pharmaceutical formulations, active pharmaceutical ingredients (API), biotech & biological formulations, medical devices and ayurvedic medicines.

It posted a turnover of ₹1,723.5 crore in 2023-24.

Mankind Pharma is India’s fourth largest pharmaceutical company by market share.

The company is present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS and respiratory.

In the consumer healthcare business, the company operates in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations.

In a regulatory filing post market hours, Mankind Pharma said that it has entered into a definitive agreement to acquire a 100 per cent stake in BSV from Advent, subject to closing related adjustments.

According to the company, the strategic move marks a significant leap, positioning it as a market leader in the Indian women's health and fertility drug market.

The acquisition is also expected to give it access to other high entry barrier products in critical care with established complex R&D tech platforms.

Mankind Pharma added that BSV has also developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and has a robust branded product portfolio.

This is spread across women's health, fertility and critical care, with a few of its marque brands enjoying a strong leadership position in their respective therapy areas.

“BSV’s acquisition represents a pivotal milestone in Mankind’s journey, establishing us as market leader in Indian women’s health & fertility segment." Rajeev Juneja, vice-chairman and managing director, Mankind Pharma said.